NEW YORK, April 2 - Gene Logic of Gaithersburg, Md., today announced the completion of its $52 million acquisition of TherImmune Research.
Gene Logic paid TherImmune shareholders approximately $30.9 million in cash, and issued 4 million shares of common stock, with a value of approximately $21.2 million, based on the closing price of its stock
The company announced the acquisition in February.